Page 1783 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 102 Immune Checkpoint Blockade in Hematologic Malignancies 1587

results from a randomized, double-blind, multicenter phase II study. and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
J Clin Oncol 30(17):2046–2054, 2012. Blood 110(1):296–304, 2007.
9. Ansell SM, et al: Phase I study of ipilimumab, an anti-CTLA-4 25. Yousef S, et al: Immunomodulatory molecule PD-L1 is expressed on
monoclonal antibody, in patients with relapsed and refractory B-cell malignant plasma cells and myeloma-propagating pre-plasma cells in
non-Hodgkin lymphoma. Clin Cancer Res 15(20):6446–6453, 2009. the bone marrow of multiple myeloma patients. Blood Cancer J 5:e285,
10. Dong H, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a 2015.
potential mechanism of immune evasion. Nat Med 8(8):793–800, 2002. 26. Porrata LF, Litzow MR, Markovic SN: Immune reconstitution after
11. Ahmadzadeh M, et al: Tumor antigen-specific CD8 T cells infiltrating autologous hematopoietic stem cell transplantation. Mayo Clin Proc
the tumor express high levels of PD-1 and are functionally impaired. 76(4):407–412, 2001.
Blood 114(8):1537–1544, 2009. 27. Armand P, et al: Disabling immune tolerance by programmed death-1
12. Rosenwald A, et al: Molecular diagnosis of primary mediastinal B cell blockade with pidilizumab after autologous hematopoietic stem-cell
lymphoma identifies a clinically favorable subgroup of diffuse large B cell transplantation for diffuse large B-cell lymphoma: results of an inter-
lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851–862, national phase II trial. J Clin Oncol 31(33):4199–4206, 2013.
2003. 28. Bashey A, et al: CTLA4 blockade with ipilimumab to treat relapse of
13. Weber JS, D’Angelo SP, Minor D, et al: Nivolumab versus chemotherapy malignancy after allogeneic hematopoietic cell transplantation. Blood
in patients with advanced melanoma who progressed after anti-CTLA-4 113(7):1581–1588, 2009.
treatment (CheckMate 037): a randomized, controlled, open-label, phase 29. Davids MS, Kim HT, Costello C, et al: A Multicenter Phase I Study
3 trial. Lancet Oncol 4:375–384, 2015. of CTLA4 Blockade with Ipilimumab for Relapsed Hematologic
14. Topalian SL, et al: Safety, activity, and immune correlates of anti-PD-1 Malignancies after Allogeneic Hematopoietic Cell Transplantation. Blood
antibody in cancer. N Engl J Med 366(26):2443–2454, 2012. 214:3964, 2014.
15. Powles T, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical 30. Postow MA, Callahan MK, Wolchok JD: Immune Checkpoint Blockade
activity in metastatic bladder cancer. Nature 515(7528):558–562, 2014. in Cancer Therapy. J Clin Oncol 2015.
16. Brahmer JR, et al: Safety and activity of anti-PD-L1 antibody in patients 31. Taube JM, et al: Association of PD-1, PD-1 ligands, and other features
with advanced cancer. N Engl J Med 366(26):2455–2465, 2012. of the tumor immune microenvironment with response to anti-PD-1
17. Green MR, et al: Integrative analysis reveals selective 9p24.1 amplifica- therapy. Clin Cancer Res 20(19):5064–5074, 2014.
tion, increased PD-1 ligand expression, and further induction via JAK2 32. Chen BJ, et al: PD-L1 expression is characteristic of a subset of aggressive
in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomas and virus-associated malignancies. Clin Cancer Res
B-cell lymphoma. Blood 116(17):3268–3277, 2010. 19(13):3462–3473, 2013.
18. Green MR, et al: Constitutive AP-1 activity and EBV infection induce 33. Wolchok JD, et al: Guidelines for the evaluation of immune therapy
PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative activity in solid tumors: immune-related response criteria. Clin Cancer
disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611– Res 15(23):7412–7420, 2009.
1618, 2012. 34. Benson DM, Jr, et al: A phase 1 trial of the anti-KIR antibody
19. Ansell SM, et al: PD-1 blockade with nivolumab in relapsed or refractory IPH2101 in patients with relapsed/refractory multiple myeloma. Blood
Hodgkin’s lymphoma. N Engl J Med 372(4):311–319, 2015. 120(22):4324–4333, 2012.
20. Moskowitz CH, Ribrag V, Michot J-M, et al: PD-1 Blockade with the 35. Vey N, et al: A phase 1 trial of the anti-inhibitory KIR mAb IPH2101
Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with for AML in complete remission. Blood 120(22):4317–4323, 2012.
Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: 36. Grimaldi AM, et al: Abscopal effects of radiotherapy on advanced
Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood melanoma patients who progressed after ipilimumab immunotherapy.
124:290, 2014. Oncoimmunology 3:e28780, 2014.
21. Berger R, et al: Phase I safety and pharmacokinetic study of CT-011, a 37. Twyman-Saint Victor C, et al: Radiation and dual checkpoint blockade
humanized antibody interacting with PD-1, in patients with advanced activate non-redundant immune mechanisms in cancer. Nature 2015.
hematologic malignancies. Clin Cancer Res 14(10):3044–3051, 2008. 38. Wolchok JD, et al: Nivolumab plus ipilimumab in advanced melanoma.
22. Westin JR, et al: Safety and activity of PD1 blockade by pidilizumab N Engl J Med 369(2):122–133, 2013.
in combination with rituximab in patients with relapsed follicular 39. Rosenblatt J, et al: PD-1 blockade by CT-011, anti-PD-1 antibody,
lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol enhances ex vivo T-cell responses to autologous dendritic cell/myeloma
15(1):69–77, 2014. fusion vaccine. J Immunother 34(5):409–418, 2011.
23. Lesokhin AM, Ansell SM, Armand P, et al: Preliminary Results of a 40. Rosenblatt J, Avivi I, Vasir D, et al: Blockade of PD-1 in Combina-
Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed tion with Dendritic Cell/Myeloma Fusion Cell Vaccination Following
or Refractory Lymphoid Malignancies. Blood (ASH Annual Meeting Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant
Meeting Abstracts) 124:291, 2014. 19:2013.
24. Liu J, et al: Plasma cells from multiple myeloma patients express B7-H1
(PD-L1) and increase expression after stimulation with IFN-{gamma}